NCT02182544已完成3 期
Phase III Double-blind Comparative Study of WAL801CL Dry Syrup in Paediatric Perennial Allergic Rhinitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 151
- 主要终点
- Total severity scores of nasal symptoms judged by the physician
研究概览
简要总结
Study to investigate the efficacy of WAL801CL Dry Syrup in comparison with ketotifen fumarate on pediatric perennial allergic rhinitis and to evaluate the safety of WAL801CL Dry Syrup compared to ketotifen fumarate and to confirm the appropriateness of dosage of WAL801 Dry Syrup.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- — 至 15 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •15 years of age or younger
- •Body weight of 14 kg or more
- •Typical symptoms of perennial allergic rhinitis, and within 2 or higher score of serum specific immunoglobulin E (IgE) caused by house dust (HD) or mite in the data obtained with the past one year
- •"Moderate" or "Severe" in the Allergic Rhinitis Severity Classification during the observation period
- •The Patient Diary can be entered by the patient or parent
- •Outpatients
排除标准
- •Absolute necessity of treatment with a drug that may affect the evaluation of the effect of the investigational drug (e.g., anti-histamines, anti-allergics, steroid, vasopressors). Patients being treated with the following drugs, however, may be included
- •Intal® Oral or Inhalation
- •Any eye drops other than Zaditen® Eye Drop
- •External preparations (liniment, poultice)
- •Initiation of desensitisation therapy within the past 6 months
- •Onset of acute upper respiratory inflammation during the observation period
- •Nasal disease, such as acute or chronic rhinitis, nasal polyp, hypertrophic rhinitis, septal deviation*, sinusitis*, and hypertrophied adenoid*, of such a degree that the disease affects evaluation of the effect of the test drug (*: X-ray examination will be conducted if necessary)
- •That pollen (cider, ragweed, Japanese cypress, orchard grass, etc.) is a double antigen, and that the study will be conducted in the season of air-borne pollen, and symptoms may be exacerbated by pollen
- •Present or past history of a convulsive disease, such as epilepsy (convulsion threshold values may be decreased by the comparator drug, ketotifen fumarate)
- •Clinically significant abnormal changes in laboratory measurements, and thus judgement that the patient is ineligible for inclusion in this study; however, if the patient is judged as falling into Grade 2 or more according to the MHW (Ministry of health and welfare) Adverse Reaction Severity Classification Criteria, the patient will be excluded from the study
- •Clinically significant renal, hepatic or cardiac disease, or other complications, and thus judgement that the patient is ineligible for inclusion in the study; however, if the patient is judged as falling into Grade 2 or more according to the MHW Adverse Reaction Severity Classification Criteria, the patient will be excluded from the study
- •Past history of drug allergy
- •1 month, or 6 times as long as the half life of the investigational drug if it is over 1 month, will not have passed since participation in any other clinical trial study, at the time of the initiation of this study
- •Judgement by the Principal Investigator or Investigator that the patient is ineligible for inclusion in this study
研究组 & 干预措施
WAL801CL dry syrup + Placebo
Experimental
干预措施: WAL801CL dry syrup (Drug)
WAL801CL dry syrup + Placebo
Experimental
干预措施: Ketotifen fumarate dry syrup placebo (Drug)
Ketotifen fumarate dry syrup + Placebo
Active Comparator
干预措施: Ketotifen fumarate dry syrup (Drug)
Ketotifen fumarate dry syrup + Placebo
Active Comparator
干预措施: WAL 801 CL dry syrup placebo (Drug)
结局指标
主要结局
Total severity scores of nasal symptoms judged by the physician
时间窗: 2 weeks of first administration of study drug
次要结局
- Nasal symptom score in the diary(2 weeks)
- Number of patients with abnormal changes from baseline in laboratory tests (hematology, biochemistry, urinalysis)(Baseline and week 2)
- Total scores for nasal symptoms in the diary(2 weeks of first administration of study drug)
- Occurrence of adverse events(up to 2 weeks after administration of study drug)
- Severity score for allergic rhinitis according to the Allergic Rhinitis Severity Classification(2 weeks)
- Impression of the patient or the parent(week 2 after first administration of study drug)
- Severity score for each nasal symptom given by the physician(2 weeks of first administration of study drug)
研究者
相似试验
已完成
3 期
WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis PatientsDermatitis, AtopicNCT02182557Boehringer Ingelheim162
已完成
3 期
WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis PatientsDermatitis, AtopicNCT02182570Boehringer Ingelheim62
已完成
3 期
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)Benign Prostatic HyperplasiaNCT00127179Organon and Co600
尚未招募
1 期
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant TumorsAdvanced Malignant NeoplasmNCT06394713Qilu Pharmaceutical Co., Ltd.60
已完成
3 期
HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and AdolescentsAsthmaNCT01147848GlaxoSmithKline810